GlassScriptPhysician profile
Michael Unruh
NPI 1104036532
$1,004.73
in general payments reported to CMS, 2019-2025
19 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $89.52 · 2021: $143 · 2022: $106 · 2023: $128 · 2024: $83.20 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $310 · Education: $33.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.14 |
| Education | $33.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $172.61 | 2019-2025 | Covera, Lutonix Drug Coated Balloon |
| Otsuka America Pharmaceutical, INC. | $129.86 | 2019-2025 | Jynarque |
| Amgen INC. | $104.58 | 2020-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $65.29 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $60.00 | 2021-2023 | Farxiga |
| Vifor Pharma, INC. | $54.42 | 2019 | |
| Opko Pharmaceuticals, LLC | $53.14 | 2021-2024 | Rayaldee |
| Travere Therapeutics, INC. | $44.07 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $41.05 | 2022-2024 | Lupkynis |
| Daiichi Sankyo INC. | $39.15 | 2019-2024 | Injectafer |
| Alexion Pharmaceuticals, INC. | $38.85 | 2019 | |
| Glaxosmithkline, LLC. | $33.94 | 2022-2025 | Benlysta |
| Fresenius USA Marketing, INC. | $31.52 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $25.24 | 2025 | Keveyis |
| Calliditas Therapeutics US INC. | $24.47 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $24.25 | 2019 | |
| Horizon Therapeutics Plc | $23.52 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.70 | 2023 | |
| Ascendis Pharma Endocrinology INC | $18.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Unruh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.